ESMO – European Society for Medical Oncology shared a post on LinkedIn:
“Clinical Trials presented at ELCC25 evaluated the efficacy and safety of new treatments for advanced/metastatic RAS-mutated NSCLC.
According to updated data from the KRYSTAL-7 phase II trial, adagrasib plus pembrolizumab continued to have encouraging efficacy in patients with KRASG12C-mutated NSCLC and PD-L1 ≥50%. Median progression-free survival (PFS) was 27.7 months but high rates of grade ≥3 adverse events were noted.
In an updated analysis from the KROCUS phase II trial investigating fulzerasib plus cetuximab in untreated patients with KRASG12C-mutated NSCLC, median PFS was 12.5 months with consistent results across levels of PD-L1 expression and manageable toxicity.
Promising phase I/Ib trial findings were also presented for daraxonrasib in previously treated RAS-mutated NSCLC.
Read the full news article in the ESMO Daily Reporter.”